{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:46:44Z","timestamp":1782215204628,"version":"3.54.5"},"reference-count":71,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>A significant increase in the number of viruses causing unexpected illnesses and epidemics among humans, wildlife and livestock has been observed in recent years. These new or re-emerging viruses have often caught the scientific community off-guard, without sufficient knowledge to combat them, as shown by the current coronavirus pandemic. The bunyaviruses, together with the flaviviruses and filoviruses, are the major etiological agents of viral hemorrhagic fever, and several of them have been listed as priority pathogens by the World Health Organization for which insufficient countermeasures exist. Based on new techniques allowing rapid analysis of the repertoire of protective antibodies induced during infection, combined with atomic-level structural information on viral surface proteins, structural vaccinology is now instrumental in the combat against newly emerging threats, as it allows rapid rational design of novel vaccine antigens. Here, we discuss the contribution of structural vaccinology and the current challenges that remain in the search for an efficient vaccine against some of the deadliest bunyaviruses.<\/jats:p>","DOI":"10.3390\/v13091766","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T23:55:22Z","timestamp":1630972522000},"page":"1766","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Input of Structural Vaccinology in the Search for Vaccines against Bunyaviruses"],"prefix":"10.3390","volume":"13","author":[{"given":"Alexandra","family":"Serris","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Tropical Medicine, H\u00f4pital Universitaire Necker-Enfants Malades, Assistance Publique\u2014H\u00f4pitaux de Paris, Universit\u00e9 de Paris, 75015 Paris, France"},{"name":"Structural Virology Unit, Institut Pasteur, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.20151960","article-title":"Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design","volume":"213","author":"Rappuoli","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.cell.2018.02.054","article-title":"Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines","volume":"172","author":"Rey","year":"2018","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"eaaj1879","DOI":"10.1126\/sciimmunol.aaj1879","article-title":"Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors","volume":"1","author":"Gilman","year":"2016","journal-title":"Sci. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ruckwardt, T.J., Morabito, K.M., Phung, E., Crank, M.C., Costner, P.J., Holman, L.A., Chang, L.A., Hickman, S.P., Berkowitz, N.M., and Gordon, I.J. (2021). Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: A phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respir. Med.","DOI":"10.1016\/S2213-2600(21)00098-9"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00705-019-04253-6","article-title":"Taxonomy of the order Bunyavirales: Update 2019","volume":"164","author":"Abudurexiti","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.aivir.2017.02.002","article-title":"The Envelope Proteins of the Bunyavirales","volume":"98","author":"Rey","year":"2017","journal-title":"Adv. Virus Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bowden, T.A., Bitto, D., McLees, A., Yeromonahos, C., Elliott, R.M., and Huiskonen, J.T. (2013). Orthobunyavirus Ultrastructure and the Curious Tripodal Glycoprotein Spike. PLOS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003374"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.celrep.2016.06.039","article-title":"A Molecular-Level Account of the Antigenic Hantaviral Surface","volume":"16","author":"Li","year":"2016","journal-title":"Cell Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2020.08.023","article-title":"The Hantavirus Surface Glycoprotein Lattice and Its Fusion Control Mechanism","volume":"183","author":"Serris","year":"2020","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1128\/JVI.01191-08","article-title":"Three-Dimensional Organization of Rift Valley Fever Virus Revealed by Cryoelectron Tomography","volume":"82","author":"Freiberg","year":"2008","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41467-019-08832-8","article-title":"Orthobunyavirus spike architecture and recognition by neutralizing antibodies","volume":"10","author":"Hellert","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9937","DOI":"10.1074\/jbc.RA118.002494","article-title":"Potassium is a trigger for conformational change in the fusion spike of an enveloped RNA virus","volume":"293","author":"Punch","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101669","DOI":"10.1016\/j.isci.2020.101669","article-title":"Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein","volume":"23","author":"Wright","year":"2020","journal-title":"iScience"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1128\/JVI.79.10.6152-6161.2005","article-title":"Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins","volume":"79","author":"Smith","year":"2005","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0042-6822(83)90182-4","article-title":"Biological activities of monoclonal antibodies reactive with antigenic sites mapped on the G1 glycoprotein of La Crosse virus","volume":"129","author":"Kingsford","year":"1983","journal-title":"Virology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e00482-20","DOI":"10.1128\/mSphere.00482-20","article-title":"Humoral Immunity to Hantavirus Infection","volume":"5","author":"Engdahl","year":"2020","journal-title":"mSphere"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e00028-20","DOI":"10.1128\/mBio.00028-20","article-title":"Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model","volume":"11","author":"Duehr","year":"2020","journal-title":"mBio"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1128\/CMR.00062-09","article-title":"A Global Perspective on Hantavirus Ecology, Epidemiology, and Disease","volume":"23","author":"Jonsson","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2009040","article-title":"\u201cSuper-Spreaders\u201d and Person-to-Person Transmission of Andes Virus in Argentina","volume":"383","author":"Alonso","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3201\/eid2608.200204","article-title":"Mother-to-Child Transmission of Andes Virus through Breast Milk, Chile","volume":"26","author":"Angulo","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.vaccine.2016.01.031","article-title":"Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavax\u2122) in healthy adults","volume":"34","author":"Song","year":"2016","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.idc.2006.03.003","article-title":"Category C Potential Bioterrorism Agents and Emerging Pathogens","volume":"20","author":"Mushtaq","year":"2006","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/1469-0691.12259","article-title":"Viral load and humoral immune response in association with disease severity in Puumala hantavirus-infected patients\u2014Implications for treatment","volume":"20","author":"Pettersson","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"eaat6420","DOI":"10.1126\/scitranslmed.aat6420","article-title":"Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo","volume":"10","author":"Garrido","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hooper, J., Paolino, K.M., Mills, K., Kwilas, S., Josleyn, M., Cohen, M., Somerville, B., Wisniewski, M., Norris, S., and Hill, B. (2020). A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation. Vaccines, 8.","DOI":"10.3390\/vaccines8030377"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"109086","DOI":"10.1016\/j.celrep.2021.109086","article-title":"Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection","volume":"35","author":"Engdahl","year":"2021","journal-title":"Cell Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1016\/j.vaccine.2013.07.025","article-title":"A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS)","volume":"31","author":"Hooper","year":"2013","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/157895","article-title":"Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives","volume":"2014","author":"Klasse","year":"2014","journal-title":"Adv. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e58242","DOI":"10.7554\/eLife.58242","article-title":"Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein","volume":"9","author":"Rissanen","year":"2020","journal-title":"eLife"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e46028","DOI":"10.7554\/eLife.46028","article-title":"Molecular organization and dynamics of the fusion protein Gc at the hantavirus surface","volume":"8","author":"Bignon","year":"2019","journal-title":"eLife"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rissanen, I., Krumm, S.A., Stass, R., Whitaker, A., Voss, J.E., Bruce, E.A., Rothenberger, S., Kunz, S., Burton, D.R., and Huiskonen, J.T. (2021). Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen. mBio, e0253120.","DOI":"10.1128\/mBio.02531-20"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1016\/j.celrep.2018.12.001","article-title":"A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus","volume":"25","author":"Allen","year":"2018","journal-title":"Cell Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The Pathogenesis of Rift Valley Fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1099\/jgv.0.001296","article-title":"Rift Valley fever: Biology and epidemiology","volume":"100","author":"Wright","year":"2019","journal-title":"J. Gen. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2014.01.011","article-title":"Emerging phleboviruses","volume":"5","author":"Elliott","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Faburay, B., LaBeaud, A.D., McVey, D.S., Wilson, W.C., and Richt, J.A. (2017). Current Status of Rift Valley Fever Vaccine Development. Vaccines, 5.","DOI":"10.3390\/vaccines5030029"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3201\/eid1712.111035","article-title":"Molecular Epidemiology of Rift Valley Fever Virus","volume":"17","author":"Grobbelaar","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hao, M., Zhang, G., Zhang, S., Chen, Z., Chi, X., Dong, Y., Fan, P., Liu, Y., Chen, Y., and Song, X. (2020). Characterization of Two Neutralizing Antibodies against Rift Valley Fever Virus Gn Protein. Viruses, 12.","DOI":"10.3390\/v12030259"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs","volume":"6","author":"Lagerqvist","year":"2009","journal-title":"Virol. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41564-019-0411-z","article-title":"Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus","volume":"4","author":"Wang","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ikegami, T., Balogh, A., Nishiyama, S., Lokugamage, N., Saito, T.B., Morrill, J.C., Shivanna, V., Indran, S.V., Zhang, L., and Smith, J.K. (2017). Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189250"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"91ra62","DOI":"10.1126\/scitranslmed.3002234","article-title":"Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity","volume":"3","author":"Scarselli","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa1615162","article-title":"Autochthonous Crimean\u2013Congo Hemorrhagic Fever in Spain","volume":"377","author":"Negredo","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1016\/j.vaccine.2012.08.003","article-title":"Healthy individuals\u2019 immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine","volume":"30","author":"Karlberg","year":"2012","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1016\/j.vaccine.2017.05.031","article-title":"Development of vaccines against Crimean-Congo haemorrhagic fever virus","volume":"35","author":"Dowall","year":"2017","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41564-020-00815-6","article-title":"A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model","volume":"6","author":"Hawman","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zivcec, M., Scholte, F., Spiropoulou, C.F., Spengler, J.R., and Bergeron, E. (2016). Molecular Insights into Crimean-Congo Hemorrhagic Fever Virus. Viruses, 8.","DOI":"10.3390\/v8040106"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"eaaw9535","DOI":"10.1126\/sciadv.aaw9535","article-title":"GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection","volume":"5","author":"Golden","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00293-9","article-title":"A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice","volume":"6","author":"Suschak","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1086\/343813","article-title":"High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever","volume":"186","author":"Libraty","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1128\/JVI.80.3.1340-1351.2006","article-title":"Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc \u03b3 Receptor-Dependent and -Independent Mechanisms","volume":"80","author":"Chung","year":"2006","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Fels, J.M., Maurer, D.P., Herbert, A.S., Wirchnianski, A.S., Vergnolle, O., Cross, R.W., Abelson, D.M., Moyer, C.L., Mishra, A.K., and Aguilan, J.T. (2021). Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell.","DOI":"10.1016\/j.cell.2021.05.001"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3201\/eid2504.181016","article-title":"Differences in Neuropathogenesis of Encephalitic California Serogroup Viruses","volume":"25","author":"Evans","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.4269\/ajtmh.16-0672","article-title":"Oropouche Virus: Clinical, Epidemiological, and Molecular Aspects of a Neglected Orthobunyavirus","volume":"96","author":"Figueiredo","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_60","unstructured":"(2021, August 22). Ngari Virus Is a Bunyamwera Virus Reassortant That Can Be Associated with Large Outbreaks of Hemorrhagic Fever in Africa [Internet]. [Cit\u00e9 30 Ao\u00fbt 2018], Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC479050\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1089\/10430349950017653","article-title":"DNA-based vaccine against La Crosse virus: Protective immune response mediated by neutralizing antibodies and CD4+ T cells","volume":"10","author":"Schuh","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"10278","DOI":"10.1073\/pnas.1106590108","article-title":"Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections","volume":"108","author":"Nuccitelli","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fimmu.2019.00372","article-title":"Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors","volume":"10","author":"Brisse","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Oloniniyi, O.K., Unigwe, U.S., Okada, S., Kimura, M., Koyano, S., Miyazaki, Y., Iroezindu, M.O., Ajayi, N.A., Chukwubike, C.M., and Chika-Igwenyi, N.M. (2018). Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria. PLOS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006971"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-virology-101416-042001","article-title":"New World Arenavirus Biology","volume":"4","author":"Sarute","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/514211","article-title":"Protective Efficacy of a Live Attenuated Vaccine against Argentine Hemorrhagic Fever","volume":"177","author":"Maiztegui","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coviro.2018.05.002","article-title":"Lassa virus glycoprotein: Stopping a moving target","volume":"31","author":"Hastie","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sommerstein, R., Flatz, L., Remy, M.M., Malinge, P., Magistrelli, G., Fischer, N., Sahin, M., Bergthaler, A., Igonet, S., and Ter Meulen, J. (2015). Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLOS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005276"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1073\/pnas.1702127114","article-title":"Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization","volume":"114","author":"Zeltina","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11544","DOI":"10.1038\/ncomms11544","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits","volume":"7","author":"Robinson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/9\/1766\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:56:29Z","timestamp":1760165789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/9\/1766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"references-count":71,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["v13091766"],"URL":"https:\/\/doi.org\/10.3390\/v13091766","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,4]]}}}